2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2 · Dec 24, 2024 · US
Inhibitors of CD40-TRAF6 interaction
US9408829B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9408829-B2 |
| Application number | US-201314417708-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2013 |
| Priority date | Aug 27, 2012 |
| Publication date | Aug 9, 2016 |
| Grant date | Aug 9, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a subject having a disease selected from atherosclerosis, obesity-associated insulin resistance, obesity-associated adipose tissue inflammation, hepatosteatosis, peritonitis and sepsis, wherein said method comprises administering to a subject in need of such treatment a compound selected from the group consisting of: wherein said compound blocks CD40-TRAF6 interaction, thereby treating the said disease.
Assignees
Inventors
Classifications
Drugs for skeletal disorders · CPC title
Drugs for dermatological disorders · CPC title
- A61K31/381Primary
having five-membered rings · CPC title
having nitrogen atoms of imino groups further bound to halogen atoms · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9408829B2 cover?
- The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.
- Who is the assignee on this patent?
- Ludwig-Maximilians-Universitaet Muenchen, Maastricht Univ, Acad Ziekenhuis Maastricht, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/381. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).